PDS Biotechnology Corp. (PDSB)
1.055
+0.02
(+2.43%)
USD |
NASDAQ |
Jun 10, 16:00
1.03
-0.02
(-2.37%)
After-Hours: 20:00
PDS Biotechnology Enterprise Value : 51.69M for June 9, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 09, 2026 | 51.69M |
| June 08, 2026 | 50.02M |
| June 05, 2026 | 51.13M |
| June 04, 2026 | 62.30M |
| June 03, 2026 | 54.48M |
| June 02, 2026 | 58.95M |
| June 01, 2026 | 57.83M |
| May 29, 2026 | 54.48M |
| May 28, 2026 | 53.92M |
| May 27, 2026 | 56.16M |
| May 26, 2026 | 55.60M |
| May 22, 2026 | 61.18M |
| May 21, 2026 | 58.95M |
| May 20, 2026 | 51.69M |
| May 19, 2026 | 50.02M |
| May 18, 2026 | 60.06M |
| May 15, 2026 | 68.99M |
| May 14, 2026 | 74.02M |
| May 13, 2026 | 68.44M |
| May 12, 2026 | 55.60M |
| May 11, 2026 | 66.76M |
| May 08, 2026 | 63.97M |
| May 07, 2026 | 57.83M |
| May 06, 2026 | 53.37M |
| May 05, 2026 | 53.37M |
| Date | Value |
|---|---|
| May 04, 2026 | 50.02M |
| May 01, 2026 | 48.94M |
| April 30, 2026 | 48.51M |
| April 29, 2026 | 47.80M |
| April 28, 2026 | 54.48M |
| April 27, 2026 | 46.11M |
| April 24, 2026 | 44.46M |
| April 23, 2026 | 46.00M |
| April 22, 2026 | 66.20M |
| April 21, 2026 | 68.99M |
| April 20, 2026 | 66.20M |
| April 17, 2026 | 67.32M |
| April 16, 2026 | 65.64M |
| April 15, 2026 | 70.11M |
| April 14, 2026 | 53.37M |
| April 13, 2026 | 55.04M |
| April 10, 2026 | 54.48M |
| April 09, 2026 | 53.92M |
| April 08, 2026 | 49.46M |
| April 07, 2026 | 45.44M |
| April 06, 2026 | 37.76M |
| April 02, 2026 | 29.64M |
| April 01, 2026 | 28.04M |
| March 31, 2026 | 27.97M |
| March 30, 2026 | 20.16M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Abeona Therapeutics, Inc. | 164.82M |
| ACADIA Pharmaceuticals, Inc. | 2.936B |
| Alnylam Pharmaceuticals, Inc. | 39.69B |
| Savara, Inc. | 837.60M |
| Vericel Corp. | 1.840B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -7.349M |
| Total Expenses (Quarterly) | 7.349M |
| EPS Diluted (Quarterly) | -0.1324 |
| Earnings Yield | -63.56% |
| Normalized Earnings Yield | -63.56 |